Sputum is reduced in COPD following treatment with benralizumab.

We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens or . Thus, benralizumab may have an indirect effect upon airway bacterial load.